Last reviewed · How we verify
BRL29060A
BRL29060A is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.
BRL29060A is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses. Used for Asthma.
At a glance
| Generic name | BRL29060A |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Leukotriene receptor antagonist |
| Target | CysLT1 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Immunology |
| Phase | Phase 3 |
Mechanism of action
The drug antagonizes cysteinyl leukotriene receptors (CysLT1 and/or CysLT2), which are key mediators of inflammation and bronchoconstriction. By blocking these receptors, BRL29060A reduces the inflammatory cascade involved in asthma and allergic airway disease, decreasing mucus production, airway edema, and smooth muscle contraction.
Approved indications
- Asthma
Common side effects
- Headache
- Dyspepsia
- Elevated liver enzymes
Key clinical trials
- Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD) (PHASE2)
- BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PHASE3)
- Social Anxiety Disorder Study Of Paroxetine (PHASE3)
- Long-term Study Of Paroxetine in Women and Men (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRL29060A CI brief — competitive landscape report
- BRL29060A updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI